| A drug burden index to define the functional burden of medications in older people SN Hilmer, DE Mager, EM Simonsick, Y Cao, SM Ling, BG Windham, ... Archives of internal medicine 167 (8), 781-787, 2007 | 871 | 2007 |
| General pharmacokinetic model for drugs exhibiting target-mediated drug disposition DE Mager, WJ Jusko Journal of pharmacokinetics and pharmacodynamics 28, 507-532, 2001 | 654 | 2001 |
| Testosterone concentrations in diabetic and nondiabetic obese men S Dhindsa, MG Miller, CL McWhirter, DE Mager, H Ghanim, A Chaudhuri, ... Diabetes care 33 (6), 1186-1192, 2010 | 463 | 2010 |
| Diversity of mechanism-based pharmacodynamic models DE Mager, E Wyska, WJ Jusko Drug metabolism and disposition 31 (5), 510-518, 2003 | 421 | 2003 |
| Caloric restriction and intermittent fasting alter spectral measures of heart rate and blood pressure variability in rats DE Mager, R Wan, M Brown, A Cheng, P Wareski, DR Abernethy, ... The FASEB Journal 20 (6), 631-637, 2006 | 335 | 2006 |
| Drug burden index score and functional decline in older people SN Hilmer, DE Mager, EM Simonsick, SM Ling, BG Windham, TB Harris, ... The American journal of medicine 122 (12), 1142-1149. e2, 2009 | 279 | 2009 |
| Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition DE Mager, W Krzyzanski Pharmaceutical research 22, 1589-1596, 2005 | 253 | 2005 |
| Target-mediated drug disposition and dynamics DE Mager Biochemical pharmacology 72 (1), 1-10, 2006 | 251 | 2006 |
| Pharmacodynamic drug–drug interactions J Niu, RM Straubinger, DE Mager Clinical Pharmacology & Therapeutics 105 (6), 1395-1406, 2019 | 226 | 2019 |
| Physical and cognitive performance and burden of anticholinergics, sedatives, and ACE inhibitors in older women YJ Cao, DE Mager, EM Simonsick, SN Hilmer, SM Ling, BG Windham, ... Clinical Pharmacology & Therapeutics 83 (3), 422-429, 2008 | 219 | 2008 |
| Dose equivalency evaluation of major corticosteroids: pharmacokinetics and cell trafficking and cortisol dynamics DE Mager, SX Lin, RA Blum, CD Lates, WJ Jusko The Journal of Clinical Pharmacology 43 (11), 1216-1227, 2003 | 174 | 2003 |
| Merging systems biology with pharmacodynamics R Iyengar, S Zhao, SW Chung, DE Mager, JM Gallo Science translational medicine 4 (126), 126ps7-126ps7, 2012 | 170 | 2012 |
| Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment‐resistant bipolar depression X Zhao, SLV Venkata, R Moaddel, DA Luckenbaugh, NE Brutsche, ... British journal of clinical pharmacology 74 (2), 304-314, 2012 | 162 | 2012 |
| Physiological modeling of formulated and crystalline 3, 3′-diindolylmethane pharmacokinetics following oral administration in mice MJ Anderton, MM Manson, R Verschoyle, A Gescher, WP Steward, ... Drug Metabolism and Disposition 32 (6), 632-638, 2004 | 161 | 2004 |
| Scaling pharmacodynamics from in vitro and preclinical animal studies to humans DE Mager, S Woo, WJ Jusko Drug metabolism and pharmacokinetics 24 (1), 16-24, 2009 | 160 | 2009 |
| Pharmacodynamic modeling of time‐dependent transduction systems DE Mager, WJ Jusko Clinical Pharmacology & Therapeutics 70 (3), 210-216, 2001 | 147 | 2001 |
| Development of translational pharmacokinetic–pharmacodynamic models DE Mager, WJ Jusko Clinical Pharmacology & Therapeutics 83 (6), 909-912, 2008 | 133 | 2008 |
| Mechanism-based pharmacodynamic modeling MA Felmlee, ME Morris, DE Mager Computational toxicology: volume I, 583-600, 2012 | 131 | 2012 |
| Quantitative structure–pharmacokinetic/pharmacodynamic relationships DE Mager Advanced drug delivery reviews 58 (12-13), 1326-1356, 2006 | 122 | 2006 |
| Application of pharmacokinetic and pharmacodynamic analysis to the development of liposomal formulations for oncology S Ait-Oudhia, DE Mager, RM Straubinger Pharmaceutics 6 (1), 137-174, 2014 | 116 | 2014 |
